Drug the undruggable

Challenge: Many high-value disease drivers are inside cells and can’t be addressed with antibodies or small molecules.

Solution: RNA therapeutics silence gene expression at the source, enabling first-in-class mechanisms.

Challenge: Systemic RNA exposure can limit efficacy and safety.

Solution: GalNAc delivers to hepatocytes for metabolic disease; AOCs (Antibody-Oligo-Conjugates) deliver into other cell types.

Challenge: Pharmaceutical products need clear translation: durable effect, biomarkers, and manufacturability.

Solution: Long-acting knockdown with clean PK/PD readouts and conjugation formats compatible with scale-up and repeat dosing.